Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Diffuse large B-cell lymphoma Friedberg JW; Fisher RIHematol Oncol Clin North Am 2008[Oct]; 22 (5): 941-52, ixDiffuse large B-cell lymphoma (DLBCL) remains a curable lymphoma, with improved outcome resulting in large part from the incorporation of rituximab in standard regimens. The disease is heterogeneous clinically, morphologically, and molecularly. Recent insights into the molecular heterogeneity of DLBCL are beginning to yield novel therapeutics with significant promise for key subsets of patients. Although cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone chemotherapy with rituximab remains a standard therapeutic approach for most patients who have DLBCL, it is anticipated that novel agents will be included in treatment regimens for many patients in the near future.|Antibodies, Monoclonal, Murine-Derived[MESH]|Antibodies, Monoclonal/therapeutic use[MESH]|Antineoplastic Combined Chemotherapy Protocols/*therapeutic use[MESH]|Cyclophosphamide/therapeutic use[MESH]|Daunorubicin/therapeutic use[MESH]|Humans[MESH]|Lymphoma, Large B-Cell, Diffuse/*drug therapy/genetics/pathology[MESH]|Prednisone/therapeutic use[MESH]|Rituximab[MESH]|Treatment Outcome[MESH]|Vincristine/therapeutic use[MESH] |